Blockchain Registration Transaction Record

Vycor Medical Announces Q2 2026 Results: VBAS Revenue Dips, NovaVision Grows

Vycor Medical reports Q2 2026 financials: VBAS revenue dips 17% in international markets, NovaVision grows 17%. New studies support VBAS safety and efficacy. OTCQB: VYCO.

Vycor Medical's financial results are significant for investors and healthcare professionals alike. The company's VBAS device is a minimally invasive surgical tool that can improve patient outcomes, and the new clinical studies reinforce its benefits over traditional methods. For patients, this means safer tumor resections with fewer neurological deficits. For investors, the company's performance indicates stability in a niche market, with NovaVision's growth potential in the vision rehabilitation space. The results also highlight the company's commitment to evidence-based medicine, which could drive future adoption and market expansion. Overall, this news matters because it showcases innovation in medical devices and therapies that can directly impact patient lives and offers insights into the financial health of a player in the neuro-medical field.